Novo Nordisk to acquire clinical-stage drugmaker Akero Therapeutics
MLex Summary: Drug manufacturer Novo Nordisk intends to purchase metabolic disease drugmaker Akero Therapeutics, which developed a treatment for MASH disorder that is currently in Phase III clinical trials in the...To view the full article, register now.
Already a subscriber? Click here to view full article